Functional and Structural Features of Cholangiocytes in Health and Disease

Overview

Journal Cell Mol Gastroenterol Hepatol

Specialty Gastroenterology

Date 2015 Aug 15

PMID 26273695

Citations 57

Authors

Luca Maroni

Bai Haibo

Debolina Ray

Tianhao Zhou

Ying Wan

Fanyin Meng

Marco Marzioni

Gianfranco Alpini

Affiliations

Soon will be listed here.

Abstract

Cholangiocytes are the epithelial cells that line the bile ducts. Along the biliary tree, two different kinds of cholangiocytes exist; small and large cholangiocytes. Each type has important differences in their biological role in physiological and pathological conditions. In response to injury, cholangiocytes become reactive and acquire a neuroendocrine-like phenotype with the secretion of a number of peptides. These molecules act in an autocrine/paracrine fashion to modulate cholangiocyte biology and determine the evolution of biliary damage. The failure of such mechanisms is believed to influence the progression of cholangiopathies, a group of diseases that selectively target biliary cells. Therefore, the understanding of mechanisms regulating cholangiocyte response to injury is expected to foster the development of new therapeutic options to treat biliary diseases. In the present review, we will discuss the most recent findings in the mechanisms driving cholangiocyte adaptation to damage, with particular emphasis on molecular pathways that are susceptible of therapeutic intervention. Morphogenic pathways (Hippo, Notch, Hedgehog), which have been recently shown to regulate biliary ontogenesis and response to injury, will also be reviewed. In addition, the results of ongoing clinical trials evaluating new drugs for the treatment of cholangiopathies will be discussed.

Citing Articles

Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments.

Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E Cells. 2024; 13(19.

PMID: 39404413 PMC: 11475195. DOI: 10.3390/cells13191650.

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis.

Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E Cells. 2024; 13(18.

PMID: 39329760 PMC: 11429758. DOI: 10.3390/cells13181580.

The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease.

Shen Q, Yang M, Wang S, Chen X, Chen S, Zhang R Front Endocrinol (Lausanne). 2024; 15:1374644.

PMID: 39175576 PMC: 11338765. DOI: 10.3389/fendo.2024.1374644.

Chemically Defined Organoid Culture System for Cholangiocyte Differentiation.

Wang Z, Ye S, van der Laan L, Schneeberger K, Masereeuw R, Spee B Adv Healthc Mater. 2024; 13(30):e2401511.

PMID: 39044566 PMC: 11616262. DOI: 10.1002/adhm.202401511.

Exploring the Pathogenesis of Autoimmune Liver Diseases from the Heterogeneity of Target Cells.

Qiu Z, Huang L, Wang X, Wang Z, Li X, Feng B J Clin Transl Hepatol. 2024; 12(7):659-666.

PMID: 38993508 PMC: 11233981. DOI: 10.14218/JCTH.2023.00531.

References

Tsuda M, Moritoki Y, Lian Z, Zhang W, Yoshida K, Wakabayashi K . Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2011; 55(2):512-21. DOI: 10.1002/hep.24748. View

Folseraas T, Liaskou E, Anderson C, Karlsen T . Genetics in PSC: what do the "risk genes" teach us?. Clin Rev Allergy Immunol. 2014; 48(2-3):154-64. DOI: 10.1007/s12016-014-8417-z. View

Tchorz J, Kinter J, Muller M, Tornillo L, Heim M, Bettler B . Notch2 signaling promotes biliary epithelial cell fate specification and tubulogenesis during bile duct development in mice. Hepatology. 2009; 50(3):871-9. DOI: 10.1002/hep.23048. View

Fabris L, Cadamuro M, Libbrecht L, Raynaud P, Spirli C, Fiorotto R . Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. Hepatology. 2007; 47(2):719-28. DOI: 10.1002/hep.22015. View

Oertelt S, Lian Z, Cheng C, Chuang Y, Padgett K, He X . Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol. 2006; 177(3):1655-60. DOI: 10.4049/jimmunol.177.3.1655. View

Yimlamai D, Christodoulou C, Galli G, Yanger K, Pepe-Mooney B, Gurung B . Hippo pathway activity influences liver cell fate. Cell. 2014; 157(6):1324-1338. PMC: 4136468. DOI: 10.1016/j.cell.2014.03.060. View

Mancinelli R, Franchitto A, Gaudio E, Onori P, Glaser S, Francis H . After damage of large bile ducts by gamma-aminobutyric acid, small ducts replenish the biliary tree by amplification of calcium-dependent signaling and de novo acquisition of large cholangiocyte phenotypes. Am J Pathol. 2010; 176(4):1790-800. PMC: 2843470. DOI: 10.2353/ajpath.2010.090677. View

Zhang N, Bai H, David K, Dong J, Zheng Y, Cai J . The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell. 2010; 19(1):27-38. PMC: 2925178. DOI: 10.1016/j.devcel.2010.06.015. View

Hov J, Keitel V, Laerdahl J, Spomer L, Ellinghaus E, ElSharawy A . Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One. 2010; 5(8):e12403. PMC: 2928275. DOI: 10.1371/journal.pone.0012403. View

10.

Hirschfield G, Mason A, Luketic V, Lindor K, Gordon S, Mayo M . Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2014; 148(4):751-61.e8. DOI: 10.1053/j.gastro.2014.12.005. View

11.

Benedetti A, Bassotti C, Rapino K, Marucci L, JEZEQUEL A . A morphometric study of the epithelium lining the rat intrahepatic biliary tree. J Hepatol. 1996; 24(3):335-42. DOI: 10.1016/s0168-8278(96)80014-6. View

12.

Hirschfield G, Liu X, Xu C, Lu Y, Xie G, Lu Y . Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009; 360(24):2544-55. PMC: 2857316. DOI: 10.1056/NEJMoa0810440. View

13.

Marzioni M, Glaser S, Francis H, Marucci L, Benedetti A, Alvaro D . Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology. 2005; 128(1):121-37. DOI: 10.1053/j.gastro.2004.10.002. View

14.

Lindor K, Kowdley K, Luketic V, Harrison M, McCashland T, Befeler A . High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009; 50(3):808-14. PMC: 2758780. DOI: 10.1002/hep.23082. View

15.

Wakabayashi K, Lian Z, Moritoki Y, Lan R, Tsuneyama K, Chuang Y . IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology. 2006; 44(5):1240-9. DOI: 10.1002/hep.21385. View

16.

Renzi A, Glaser S, DeMorrow S, Mancinelli R, Meng F, Franchitto A . Melatonin inhibits cholangiocyte hyperplasia in cholestatic rats by interaction with MT1 but not MT2 melatonin receptors. Am J Physiol Gastrointest Liver Physiol. 2011; 301(4):G634-43. PMC: 3191552. DOI: 10.1152/ajpgi.00206.2011. View

17.

Francis H, DeMorrow S, Franchitto A, Venter J, Mancinelli R, White M . Histamine stimulates the proliferation of small and large cholangiocytes by activation of both IP3/Ca2+ and cAMP-dependent signaling mechanisms. Lab Invest. 2011; 92(2):282-94. PMC: 3293651. DOI: 10.1038/labinvest.2011.158. View

18.

Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger B . Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology. 2009; 136(7):2325-33. PMC: 2743481. DOI: 10.1053/j.gastro.2009.02.051. View

19.

Manousou P, Kolios G, Drygiannakis I, Koulentaki M, Pyrovolaki K, Voumvouraki A . CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid. Clin Exp Immunol. 2013; 172(1):9-15. PMC: 3719926. DOI: 10.1111/cei.12032. View

20.

Lleo A, Gershwin M, Mantovani A, Invernizzi P . Towards common denominators in primary biliary cirrhosis: the role of IL-12. J Hepatol. 2011; 56(3):731-3. PMC: 3580217. DOI: 10.1016/j.jhep.2011.05.040. View